Novo Nordisk stock plummeted Tuesday after the drugmaker reported lighter-than-expected June-quarter sales for its new obesity-fighting pill, intensifying a high-stakes market battle with rival Eli Lilly. According to Investor’s Business Daily, the company’s Wegovy pill generated about $496 million during the second quarter, missing analyst forecasts of $509 million and sending shares down more than … Read more
Popular weight loss drugs like Ozempic and Wegovy could deliver measurable economic benefits by significantly reducing employee sick leave, according to an economic study published this month by the National Bureau of Economic Research. The research found that GLP-1 medications resulted in workers taking 17 percent less long-term sick leave, translating to substantial financial savings … Read more
Researchers at Yale University found that patients can obtain GLP-1 prescriptions from online platforms in as little as five minutes using fake profiles, raising significant concerns about the level of clinical oversight in direct-to-consumer healthcare. A study published July 6 in the JAMA medical journal revealed that 45 out of 49 websites tested issued prescriptions … Read more
Kinney Drugs will launch the Medicare GLP-1 Bridge Program next Wednesday, providing eligible Medicare Part D patients access to weight-loss medications like Wegovy, Zepbound, and Fundayo for a $50 monthly copay through 2027. According to Shannon Miller, vice president of healthcare operations at Kinney Drugs, the pilot program aims to bridge the coverage gap for … Read more
The Trillion-Dollar Shift: Navigating the Future of Healthcare Investing The economic landscape of healthcare is undergoing a seismic shift. According to the Committee for a Responsible Federal Budget, federal healthcare spending is projected to climb from less than $2 trillion today to more than $3 trillion within a decade. View this post on Instagram about … Read more
The GLP-1 Gold Rush: Is India Ready for the Future of Weight Loss? For decades, weight loss in India was a battle of willpower, restrictive diets, and grueling gym hours. But a seismic shift is happening. The conversation has moved from “which diet works” to “which injectable is better.” Drugs like Mounjaro and Ozempic, originally … Read more
Weight-Loss Drugs and Vision Loss: What the Latest Research Reveals Recent studies are raising concerns about a potential link between semaglutide-based weight-loss medications, like Wegovy and Ozempic, and an increased risk of ischemic optic neuropathy (ION), a condition that can lead to vision loss. While the research is preliminary, it’s prompting closer scrutiny of these … Read more
The Ozempic Effect: A Looming Kidney Health Crisis and the Future of Weight Loss The pursuit of a “summer body” often drives individuals to extreme measures, and the rise of weight loss drugs like Ozempic has introduced a latest layer of complexity – and potential risk. While initially designed for type 2 diabetes management, Ozempic’s … Read more
The Weight Loss Drug Rollercoaster: What Happens When You Stop Ozempic or Mounjaro? Injectable weight-loss medications like semaglutide (Ozempic) and tirzepatide (Mounjaro) have dramatically changed how obesity is treated, helping many people achieve significant weight loss. However, a growing body of research suggests these benefits may be temporary if treatment is halted. Understanding what happens … Read more
Beyond Weight Loss: How New Drugs Could Revolutionize Heart Health The rise of medications like semaglutide (Ozempic, Wegovy) has been largely focused on their dramatic effects on weight loss. Still, emerging research reveals a potentially far more significant benefit: protection against cardiovascular disease. These GLP-1 receptor agonists are now being recognized not just as diabetes … Read more